Anthem Biosciences Ltd (ANTHEM) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company concluded the financial year 2025-26 on a strong note, achieving its highest-ever quarterly revenue in Q4 FY26.
- The quarter was marked by significant year-on-year growth, with consolidated revenue increasing by 26% and Profit After Tax (PAT) surging by an impressive 130%.
- The CRDMO business segment continued to be the primary growth driver, demonstrating robust performance with a 31% year-on-year revenue increase for the quarter.
- Management highlighted that the destocking issues faced by customers in the previous year are now largely resolved, with a shift towards restocking expected to positively impact future performance.
- The company maintains a strong financial position with a significant net cash balance, reinforcing its capacity for future investments in technology, capacity expansion, and potential acquisitions.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.